10-K: ZimVie Inc. Reports FY2024 Results, Completes Spine Business Sale

ZimVie Inc. completes the sale of its spine segment and focuses on its dental business while navigating a challenging economic environment.

Summary

• ZimVie Inc. reported its FY2024 results, highlighting the completion of the sale of its spine segment on April 1, 2024, for $377 million.
• The company received net proceeds of $311.6 million from the sale, excluding the promissory note and transaction costs.
• Historical financial results of the spine segment are now classified as discontinued operations.
• ZimVie is now focused on its dental business, which includes dental implant systems, biomaterial products, and digital dentistry solutions.
• The company estimates the global tooth replacement market generated approximately $8 billion in sales in 2024.
• Net sales for continuing operations were $449.7 million in 2024, a 1.7% decrease compared to 2023.
• The company experienced a price decline in 2024, primarily related to pricing pressures on premium dental implant system sales in North America and declines in pricing in China.
• ZimVie incurred R&D expenses for continuing operations of $26.9 million in 2024.
• The company had $76.6 million in cash and cash equivalents as of December 31, 2024.
• ZimVie expects growth from its dental product offerings in 2025 but anticipates headwinds from foreign currency exchange risk and macroeconomic pressures.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company completed a strategic sale and is focusing on its core dental business, it faces challenges such as declining sales and pricing pressures. The outlook for 2025 includes both growth opportunities and potential headwinds.

Positives

• Completion of the sale of the spine segment provides ZimVie with additional capital to invest in its dental business and repay debt.
• The company is well-positioned in the growing global dental implant, biomaterials and digital dentistry market.
• ZimVie expects an overall decrease in interest expense in 2025 based on its debt position and interest rate outlook.
• The company plans to continue to focus on operational improvement initiatives to support the health of its income statement and balance sheet.

Negatives

• Net sales for continuing operations decreased by 1.7% in 2024 compared to 2023.
• The company experienced a price decline in 2024, primarily related to pricing pressures on premium dental implant system sales in North America and declines in pricing in China.
• The company anticipates headwinds from foreign currency exchange risk and macroeconomic pressures in 2025.

Risks

• The company is exposed to risks of excess and obsolete inventory.
• The company is subject to risks arising from currency exchange rate fluctuations.
• The company may be adversely affected by inflation.
• The company may have additional tax liabilities.
• Future material impairments in the carrying value of the company's long-lived or intangible assets, including goodwill, would negatively affect operating results.
• The company is subject to costly and complex laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, post-market surveillance, manufacturing, labeling and marketing of its products, non-compliance with which could adversely affect its business, financial condition and results of operations.
• The company is increasingly dependent on sophisticated information technology and if it fails to effectively maintain or protect its information systems or data, including from data breaches, its business could be adversely affected.

Future Outlook

ZimVie expects growth from its implant systems, digital dentistry and dental biomaterial product offerings in 2025, but such growth may be limited by headwinds in foreign currency exchange risk and continued macro-economic pressures in the premium tooth replacement market. The company will continue to focus on operational improvements to expand margins and expects an overall decrease in interest expense in 2025.

Industry Context

The document indicates that ZimVie operates in a highly competitive market within the medical technology industry, specifically in the dental implant and digital dentistry sectors. The company competes with other global medical technology companies and pure-play dental companies. The industry is affected by the introduction of new products and technologies and other market activities of industry participants.

Comparison to Industry Standards

• The document mentions key competitors such as The Straumann Group, Dentsply Sirona Inc., Nobel Biocare Services AG (part of Envista Holdings Corporation), Henry Schein, Inc. and Geistlich Pharma AG.
• These companies are global leaders in the dental implant and biomaterials market, and ZimVie's performance is likely benchmarked against their growth rates, profitability, and market share.
• The document also highlights the importance of technological innovation, clinical results, price, breadth of product line, scale of operations, distribution capabilities, brand reputation, medical education capabilities and customer service as key competitive factors, suggesting that ZimVie's performance in these areas is compared to industry standards.

Legal Proceedings

• The company is involved in various claims, legal proceedings and investigations regarding commercial, contractual, intellectual property, employment, product liability and other matters that arise in the normal course of business.

Stakeholder Impact

• Shareholders: The sale of the spine segment and focus on the dental business could impact shareholder value.
• Employees: Restructuring activities may result in workforce reductions.
• Customers: The company's focus on innovation and new product development aims to improve outcomes for dental patients.
• Suppliers: Changes in the company's operations and supply chain may affect its relationships with suppliers.

Next Steps

• The company plans to continue to focus on operational improvement initiatives to support the health of its income statement and balance sheet.
• The company expects to complete the restructuring plan initiated in January 2024 by the end of 2025.
• The company expects the remaining four Deferred Transfer Locations to be transferred within one year of the closing date of the sale.

Key Dates